Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Much Is the Global Pneumococcal Vaccine Market Valued at Present and by 2029?

The market size for the pneumococcal vaccine has seen considerable growth in the past few years. This expansion is predicted to continue with it projected to increase from $8.94 billion in 2024 to $9.4 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 5.2%. The substantial growth observed during the historical period can be tied to developments such as the discovery of streptococcus pneumoniae, public health consciousness, implementation of early vaccination programs, advancements in health care, and modifications in vaccine policies.

The market for pneumococcal vaccines is projected to witness significant expansion in the upcoming years, escalating to a valuation of $11.9 billion by 2029 with a CAGR of 6.1%. The anticipated growth during the forecast period can be ascribed to factors such as the emergence of new pneumococcal strains, ongoing research and development initiatives, emphasis on immunization, broadening availability of vaccines and the aging population. Key trends identified for the forecast period comprise the development of multivalent vaccines, focus on vaccinating the high-risk group, enhancing the efficacy of vaccines, initiatives to increase education and awareness, with particular attention to infant immunization.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11950&type=smp

#What Drivers Are Influencing Growth In The Pneumococcal Vaccine Market?

The rise in cases of pneumococcal contamination is anticipated to fuel the development of the pneumococcal vaccine market. Pneumococcal contamination, namely infections caused by the bacteria Streptococcus pneumoniae or pneumococcus, consists of pneumonia, bloodstream infections, ear infections, and sinus infections. The pneumococcal vaccine encourages the generation of antibodies to fight pneumococcal bacteria, reducing or eradicating bacteria and toxins that cause diseases, thereby safeguarding children, older adults, and those with compromised immune systems from various pneumococcal infections. As an illustration, the Center for Disease Control and Prevention, a US public health organization, stated in January 2022 that Pneumococcal pneumonia results in around 150,000 hospitalizations annually in the United States, representing approximately 30% of adult community-acquired pneumonia. Hence, the ascending incidence of pneumococcal contamination is stimulating the expansion of the pneumococcal vaccine market.

What Are The Main Segments Identified In The Pneumococcal Vaccine Market Research?

The pneumococcal vaccine market covered in this report is segmented –

1) By Product Type: Prevnar 13, Synflorix, Pneumovax23, Other Products

2) By Route of Administration: Intravenous, Intramuscular, Subcutaneous

3) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Distribution Channels

4) By End User: Pediatrics, Adults

Subsegments:

1) By Prevnar 13: Pediatric Formulation, Adult Formulation

2) By Synflorix: Pediatric Formulation, Adult Formulation

3) By Pneumovax23: Single-Dose Vials, Pre-Filled Syringes

4) By Other Products: PCV15 (Vaxneuvance), PCV20 (Prevnar 20), Other Regional Pneumococcal Vaccines

What Are The Leading Trends And Opportunities In The Pneumococcal Vaccine Sector?

Technological advancements are emerging as a significant trend in the pharmaceutical continuous manufacturing market, with leading industry players introducing new offerings aimed at maintaining their market positions. For instance, in December 2022, The United States Pharmacopeia (USP) unveiled the USP Advanced Manufacturing Technology Lab as well as research and development analytical solutions. This US-based non-profit organization holds both the trademark and copyright for the Pharmacopeia National Formulary (USP-NF). The role of these analytical lab services is to help drug manufacturers embrace sophisticated manufacturing technologies like pharmaceutical continuous manufacturing (PCM). This not only broadens the geographic diversity in pharmaceutical production but also enhances the resilience of the medicine supply chain. It involves describing materials, creating and qualifying methods to support and ensure the quality of PCM-based drugs.

Which Companies Play A Key Role In The Development Of The Pneumococcal Vaccine Market?

Major companies operating in the pneumococcal vaccine market include Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc, Astellas Pharma Inc., CSL Limited, Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, Serum Institute of India Private Limited, Emergent BioSolutions Inc., Walvax Biotechnology Co. Ltd, Biological E Limited, Hualan Biological Engineering Inc., Beijing Minhai Biotechnology Limited Company, NPO Petrovax Pharm LLC, Vaxcyte Inc., Panacea Biotec Ltd, Inventprise LLC, Tergene Biotech Private Limited, PnuVax Incorporated, SK Bioscience Co Ltd

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

What Are The Key Regional Developments Shaping The Pneumococcal Vaccine Market?

North America was the largest region in the pneumococcal vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pneumococcal vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=11950&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model